Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 4:20 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 41 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Hypothalamic Obesity Clear all
Completed Phase 2 Interventional Results available

Open-Label Study of Setmelanotide in Hypothalamic Obesity

NCT04725240
View directory record Official record
Conditions
Hypothalamic Obesity
Interventions
Setmelanotide
Drug
Lead sponsor
Rhythm Pharmaceuticals, Inc.
Industry
Eligibility
6 Years to 40 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
5
States / cities
San Diego, California • Gainesville, Florida • Saint Paul, Minnesota + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 7, 2025 · Synced Oct 22, 2026, 4:20 PM EDT
Completed Phase 4 Interventional

Pediatric Hypothalamic Obesity

NCT00076362
View directory record Official record
Conditions
Obesity
Interventions
Sandostatin LAR
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
6 Years to 18 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
15
States / cities
Phoenix, Arizona • Orange, California • San Francisco, California + 12 more
Source: ClinicalTrials.gov public record
Updated Sep 12, 2011 · Synced Oct 22, 2026, 4:20 PM EDT
Withdrawn Not applicable Interventional

Deep Brain Stimulation Effects in Patients With Chronic Refractory Obesity

NCT04453020
View directory record Official record
Conditions
Obesity
Interventions
DBS of the LHA
Device
Lead sponsor
donald whiting
Other
Eligibility
22 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 27, 2025 · Synced Oct 22, 2026, 4:20 PM EDT
Completed Phase 3 Interventional Results available

Phase 3 Crossover Trial of Two Formulations of Setmelanotide in Participants With Specific Gene Defects in the MC4R Pathway

NCT05194124
View directory record Official record
Conditions
Bardet-Biedl Syndrome, POMC Deficiency
Interventions
Setmelanotide 2 mg, Setmelanotide 2.5 mg, Setmelanotide 3 mg, Setmelanotide 20 mg, Setmelanotide 25 mg, Setmelanotide 30 mg
Drug
Lead sponsor
Rhythm Pharmaceuticals, Inc.
Industry
Eligibility
6 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
2
States / cities
Scottsdale, Arizona • Marshfield, Wisconsin
Source: ClinicalTrials.gov public record
Updated Nov 26, 2024 · Synced Oct 22, 2026, 4:20 PM EDT
Completed Phase 2 Interventional

An Efficacy, Safety, and Pharmacokinetics Study of Beloranib in Obese Subjects With Hypothalamic Injury

NCT02063295
View directory record Official record
Conditions
Obesity, Over-weight, Hypothalamic Injury, Craniopharyngioma
Interventions
ZGN-440 sterile diluent, ZGN-440 for injectable suspension
Drug
Lead sponsor
Zafgen, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
2
States / cities
Saint Paul, Minnesota • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jul 18, 2016 · Synced Oct 22, 2026, 4:20 PM EDT
Completed Phase 3 Interventional Results available

Setmelanotide (RM-493), Melanocortin-4 Receptor (MC4R) Agonist, in Bardet-Biedl Syndrome (BBS) and Alström Syndrome (AS) Participants With Moderate to Severe Obesity

NCT03746522
View directory record Official record
Conditions
Bardet Biedl Syndrome (BBS), Alström Syndrome (AS)
Interventions
Setmelanotide, Placebo
Drug
Lead sponsor
Rhythm Pharmaceuticals, Inc.
Industry
Eligibility
6 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
6
States / cities
San Diego, California • Springfield, Massachusetts • New York, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 1, 2023 · Synced Oct 22, 2026, 4:20 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Hypothalamic Functional Magnetic Resonance Imaging (fMRI) Response to Nutrients

NCT00686608
View directory record Official record
Conditions
Obesity
Interventions
glucose, fructose, saline
Dietary Supplement
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years to 45 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2015
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Aug 7, 2019 · Synced Oct 22, 2026, 4:20 PM EDT
Terminated Phase 4 Interventional Results available

Body Composition and Adipose Tissue in HIV

NCT03226821
View directory record Official record
Conditions
HIV Lipodystrophy Syndrome, Growth Hormone Deficiency, Body Composition
Interventions
Tesamorelin
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 68 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 19, 2026 · Synced Oct 22, 2026, 4:20 PM EDT
Completed No phase listed Observational

The TEMPO (Tracing the Effect of the MC4 Pathway in Obesity) Registry

NCT03479437
View directory record Official record
Conditions
Genetic Forms of Extreme Obesity
Interventions
Not listed
Lead sponsor
Rhythm Pharmaceuticals, Inc.
Industry
Eligibility
2 Years and older
Enrollment
303 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated May 4, 2021 · Synced Oct 22, 2026, 4:20 PM EDT
Terminated Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Free Fatty Acids, Body Weight, and Growth Hormones Secretion in Children

NCT01237041
View directory record Official record
Conditions
Obesity, Short Stature, Growth Hormone Deficiency
Interventions
Niacin First, Placebo First, Dose-Establishing Study 1 Niacin 250mg, Dose-Establishing Study 1 Niacin 500mg, Dose-Establishing Study 2 Niacin 500mg
Drug
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
7 Years to 14 Years
Enrollment
37 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2017
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 17, 2018 · Synced Oct 22, 2026, 4:20 PM EDT
Completed Not applicable Interventional Results available

Deep Brain Stimulation Effects on Weight Change and Metabolic Rate

NCT01933113
View directory record Official record
Conditions
Obesity
Interventions
Deep Brain Stimulation of the Lateral Hypothalamic Area
Device
Lead sponsor
Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)
Other
Eligibility
Not listed
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 27, 2025 · Synced Oct 22, 2026, 4:20 PM EDT
Completed Phase 2 Interventional Results available

Weight Loss Study for Patients With Obesity Due to Craniopharyngioma or Other Brain Tumor

NCT01484873
View directory record Official record
Conditions
Obesity, Overweight, Craniopharyngioma
Interventions
Exenatide
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 40 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 3, 2017 · Synced Oct 22, 2026, 4:20 PM EDT
Recruiting No phase listed Observational

Whole Transcriptome Profiling and Metabolic Phenotyping in Children With ROHHAD Syndrome

NCT02602769
View directory record Official record
Conditions
Childhood Obesity, Morbid Obesity
Interventions
Transcriptome profiling
Diagnostic Test
Lead sponsor
Columbia University
Other
Eligibility
2 Years to 20 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2026
U.S. locations
2
States / cities
Boston, New York • New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 21, 2025 · Synced Oct 22, 2026, 4:20 PM EDT
Recruiting Phase 3 Interventional

A Trial of Setmelanotide in Patients With Congenital Hypothalamic Obesity (Sub-study of NCT05774756)

NCT06760546
View directory record Official record
Conditions
Hypothalamic Obesity, Multiple Pituitary Hormone Deficiency Genetic Form, Septo-Optic Dysplasia, Optic Nerve Hypoplasia, Childhood-onset Combined Pituitary Hormone Deficiency, Pituitary Stalk Interruption Syndrome
Interventions
Setmelanotide, Placebo
Drug
Lead sponsor
Rhythm Pharmaceuticals, Inc.
Industry
Eligibility
4 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
8
States / cities
Birmingham, Alabama • Aurora, Colorado • Chicago, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated Feb 12, 2026 · Synced Oct 22, 2026, 4:20 PM EDT
Enrolling by invitation Phase 2 Interventional

A Long-Term Study of Bivamelagon in Participants With Hypothalamic Obesity (HO)

NCT07156578
View directory record Official record
Conditions
Hypothalamic Obesity
Interventions
Bivamelagon
Drug
Lead sponsor
Rhythm Pharmaceuticals, Inc.
Industry
Eligibility
12 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
6
States / cities
Aurora, Colorado • Iowa City, Iowa • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 10, 2026 · Synced Oct 22, 2026, 4:20 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Neural Functioning of Feeding Centers in Obese Youth

NCT01808846
View directory record Official record
Conditions
Obesity, Insulin Resistance
Interventions
Not listed
Lead sponsor
Yale University
Other
Eligibility
12 Years to 17 Years
Enrollment
51 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2017
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Apr 27, 2017 · Synced Oct 22, 2026, 4:20 PM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

Convergent Mechanisms Underlying Reprometabolic Syndrome in Women

NCT06686537
View directory record Official record
Conditions
Infertility, Female, Obesity
Interventions
Estradiol Patches
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 38 Years · Female only
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
2
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Oct 22, 2026, 4:20 PM EDT
Completed Phase 3 Interventional

Open-Label Extension Study of Setmelanotide

NCT06596135
View directory record Official record
Conditions
Obesity Associated With Defects in Leptin-melanocortin Pathway
Interventions
Setmelanotide
Drug
Lead sponsor
Rhythm Pharmaceuticals, Inc.
Industry
Eligibility
2 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
13
States / cities
Scottsdale, Arizona • San Diego, California • Gainesville, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Oct 22, 2026, 4:20 PM EDT
Completed Not applicable Interventional

The Hypothalamic-Pituitary-Adrenal (HPA) Axis as an Effector System in Weight Regulation

NCT00688987
View directory record Official record
Conditions
Obesity, Addison's Disease
Interventions
Hydrocortisone, Isocaloric Diet
Drug · Dietary Supplement
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2004
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jun 5, 2008 · Synced Oct 22, 2026, 4:20 PM EDT
Active, not recruiting Phase 2 Interventional

Efficacy and Safety of Phentermine/Topiramate in Youth With Hypothalamic Obesity

NCT06299891
View directory record Official record
Conditions
Hypothalamic Obesity, Hypothalamic Tumor, Craniopharyngioma
Interventions
Phentermine / Topiramate Extended Release Oral Capsule [Qsymia], Placebo
Drug · Other
Lead sponsor
Seattle Children's Hospital
Other
Eligibility
6 Years to 28 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
2
States / cities
Philadelphia, Pennsylvania • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 22, 2026, 4:20 PM EDT
Completed Phase 2 Interventional Results available

Effectiveness of Growth Hormone Releasing Hormone in Reducing Abdominal Fat in People Who Are Obese

NCT00675506
View directory record Official record
Conditions
Abdominal Obesity, Growth Hormone Deficiency
Interventions
Growth hormone releasing hormone (GHRH) 1-44, Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 55 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 13, 2017 · Synced Oct 22, 2026, 4:20 PM EDT
Active, not recruiting Phase 3 Interventional Results available

A Trial of Setmelanotide in Acquired Hypothalamic Obesity

NCT05774756
View directory record Official record
Conditions
Hypothalamic Obesity
Interventions
Setmelanotide, Placebo
Drug
Lead sponsor
Rhythm Pharmaceuticals, Inc.
Industry
Eligibility
4 Years and older
Enrollment
143 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
16
States / cities
Birmingham, Alabama • San Diego, California • Aurora, Colorado + 11 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Oct 22, 2026, 4:20 PM EDT
Completed Not applicable Interventional

Macronutrient Regulation of Ghrelin and Peptide YY

NCT02464514
View directory record Official record
Conditions
Obesity, Prader Willi Syndrome
Interventions
High carbohydrate meal, High fat meal
Other
Lead sponsor
Duke University
Other
Eligibility
5 Years to 17 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 10, 2015 · Synced Oct 22, 2026, 4:20 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Does What You Eat Affect Your Brain

NCT05626907
View directory record Official record
Conditions
Gliosis, Obesity, Eating
Interventions
Diet modification #1, Diet modification #2, Diet modification #3
Other
Lead sponsor
University of Washington
Other
Eligibility
20 Years to 40 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jul 17, 2026 · Synced Oct 22, 2026, 4:20 PM EDT